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Abstract
Cyclooxygenase (COX)-derived prostaglandins and cytochrome P450 (CYP) epoxygenase-
derived epoxyeicosatrienoic acids are important regulators of inflammation; however, functional
interactions between these pathways in the regulation of vascular inflammation in vivo have not
been studied. We investigated the relative and additive effects of endothelial CYP2J2
overexpression (Tie2-CYP2J2-Tr), global sEH disruption (Ephx2−/−), and pharmacologic COX
inhibition with indomethacin on the acute vascular inflammatory response to endotoxin in mice.
Compared to vehicle-treated wild-type C57BL/6 controls, induction of myeloperoxidase (MPO)
activity in lung and liver was similarly attenuated in Tie2-CYP2J2-Tr mice, Ephx2−/− mice and
wild-type mice treated with moderate dose indomethacin. Dual modulation of both pathways,
however, did not produce an additive anti-inflammatory effect. These findings demonstrate that
both COX and CYP epoxygenase-mediated eicosanoid metabolism are important regulators of the
acute vascular inflammatory response in vivo, and suggest that the anti-inflammatory effects of
modulating each pathway may be mediated, at least in part, by overlapping mechanisms.
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INTRODUCTION
Vascular inflammation is characterized by endothelial activation and subsequent infiltration
of leukocytes into the surrounding tissue [1]. Nuclear factor-kappa B (NF-κB) initiates and
propagates this coordinated process through transcriptional activation of cellular adhesion
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molecules (CAMs), chemokines, and cytokines [2,3]. This fundamental pathological process
plays a pivotal role in the pathogenesis of numerous acute and chronic inflammation-related
diseases such as sepsis, asthma, and cardiovascular disease (CVD). Thus, identification of
the key pathways that regulate NF-κB-dependent vascular inflammatory responses offers
enormous potential to facilitate the development of novel anti-inflammatory therapeutic
strategies.
Eicosanoids are biologically active fatty acids derived through oxidative metabolism of
arachidonic acid by the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450
(CYP) enzyme systems [4]. It is well established that COX-derived prostaglandins are
integral regulators of inflammation, such that inhibition of COX-mediated prostaglandin
biosynthesis produces potent anti-inflammatory effects in preclinical models and humans
[5]. Most notably, prostaglandin E2 (PGE2) and thromboxane A2 (TxA2) are key pro-
inflammatory products of this pathway that activate NF-κB, promote leukocyte infiltration
into tissue, and thus drive the vascular inflammatory response [6,7].
In parallel, CYP epoxygenases from the CYP2J and CYP2C subfamilies catalyze the
metabolism of arachidonic acid into epoxyeicosatrienoic acids (EETs), which have become
increasingly recognized to possess potent anti-inflammatory properties [8]. The life of
circulating EETs, however, is ephemeral as they are quickly hydrolyzed into the less potent
dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH, EPHX2). We
have previously shown that potentiation of CYP epoxygenase-derived EETs by endothelial
CYP2J2 overexpression (Tie2-CYP2J2-Tr), endothelial CYP2C8 overexpression (Tie2-
CYP2C8-Tr) or global sEH disruption (Ephx2−/−) attenuates NF-κB-dependent acute
vascular inflammatory responses in vivo [9].
Past studies have shown that inhibition of one arachidonic acid pathway may shunt
metabolism down another parallel path [10,11]. Furthermore, additive attenuation of
lipopolysaccharide (LPS)-induced pain and hypotension from simultaneous augmentation of
CYP-derived EETs in tandem with cyclooxygenase (COX) inhibition has been recently
reported [12,13]. However, functional interactions between the COX and CYP epoxygenase
pathways in the regulation of acute vascular inflammation in vivo have not been studied.
Consequently, we investigated the relative and additive effects of endothelial CYP2J2
overexpression, global sEH disruption, and pharmacologic COX inhibition on the acute
vascular inflammatory response to the endotoxin LPS, a well-established activator of NF-
κB-dependent endothelial activation and leukocyte infiltration [14].
MATERIALS AND METHODS
Chemicals
Chemicals were purchased from Sigma–Aldrich (St. Louis, MO, USA) unless otherwise
noted.
Animal
All experiments were completed in adult male and female mice on a C57BL/6 background.
Transgenic (Tr) mice that express human CYP2J2 in endothelial cells under control of the
murine Tie2 promoter and full enhancer (Tie2-CYP2J2-Tr) were developed on a pure
C57BL/6 background, as previously described [15]. A colony of mice with targeted
disruption of Ephx2 (Ephx2−/−) was rederived and backcrossed onto a C57BL/6 genetic
background for more than 10 generations [16,17]. We have previously reported significantly
higher endothelial EET biosynthesis in Tie2-CYP2J2-Tr mice and circulating epoxide:diol
ratios in Ephx2−/− mice, compared to wild-type (WT) littermates, consistent with CYP
epoxygenase overexpression and sEH disruption, respectively [9,15,17,18]. All experiments
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with Tie2-CYP2J2-Tr mice used Tr mice from multiple founder lines and WT littermates as
controls. Experiment 2, which did not involve the genetically-modified mice, utilized
commercially available C57BL/6 mice (Taconic, Hudson, NY, USA). All mice had free
access to food and water, and were housed in controlled conditions for temperature and
humidity using a 12-hour light/dark cycle. All experiments were completed in accordance
with the US National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Committee at the
University of North Carolina at Chapel Hill and the National Institute of Environmental
Health Sciences.
Experimental Protocol
Wild-type C57BL/6, Tie2-CYP2J2-Tr and Ephx2−/− mice weighing 18–31 grams were
pretreated with the nonselective COX inhibitor indomethacin (1, 2.5, 5 or 10 mg/kg) or
vehicle (0.5% carboxymethylcellulose) once daily for 3 days via oral gavage. On day 3, one
hour following indomethacin or vehicle administration, mice received a single dose of
Escherichia coli LPS (serotype O111:B4, 1,000,000 EU/mg; 10 mg/kg) or endotoxin-free
phosphate-buffered saline (PBS) by intraperitoneal injection. Mice were euthanized by CO2
inhalation 3 hours after LPS (or PBS) administration, as previously described [9]. Blood was
collected by cardiac puncture, and plasma was separated by centrifugation. Lung and liver,
highly vascularized tissues that exhibit prominent activation of NF-κB signaling and
leukocyte infiltration in vivo upon LPS administration [14,19] were snap-frozen in liquid
nitrogen and stored at −80°C for protein isolation.
Myeloperoxidase Activity
Myeloperoxidase (MPO) is a leukocyte-derived heme oxidase primarily carried by
polymorphonuclear neutrophils [20]. Since MPO enzymatic activity in parenchyma
predominantly reflects the presence of neutrophils, and correlates with
immunohistochemical detection of neutrophil margination and tissue infiltration in this
model [9], we utilized MPO functional activity as an in vivo biomarker of LPS-induced
neutrophil infiltration and the primary index of vascular inflammation in these experiments.
Briefly, frozen tissue (30 mg) was homogenized in 20 mM PBS with 10 mM N-
ethylmaleimide (pH 7.4), and centrifuged at 10,000 x g for 15 minutes at 4°C. The pellet
was resuspended in 50 mM PBS (pH 6.0) containing 0.5% hexadecyltrimethylammonium
bromide, sonicated for 30 seconds, and centrifuged at 8,000 x g for 20 minutes at 4°C. MPO
activity in the supernatant was quantified using the Fluorescent Myeloperoxidase Detection
Kit (Cell Technology, Mountain View, CA, USA), according to the manufacturer’s
instructions. Fluorescence was quantified on a FLUOstar Omega Microplate Reader
(IMGEN Technologies, Alexandria, VA, USA) at excitation/emission wavelengths of
530/590 nm.
Quantification of Eicosanoids
Plasma epoxy (8,9-, 11,12-, 14,15-EET), dihydroxy (5,6-, 8,9-, 11,12-, 14,15-DHET), and
prostaglandin (PGE2, TxB2, 6-keto-PGF1α) metabolites of arachidonic acid were quantified
using an established HPLC-MS/MS method, following solid-phase extraction, as described
[17,21]. The sum total of EETs plus DHETs and the 14,15-EET:DHET ratio were used as
biomarkers of CYP epoxygenase and sEH metabolic function, respectively [9,17]. In a
subset of experiments, plasma PGEM (a stable metabolite of PGE2) and 11-dehydro-TxB2
(a stable metabolite of TxA2) concentrations were quantified using the Prostaglandin E
Metabolite and 11-dehydro Thromboxane B2 EIA kits (Cayman Chemical, Ann Arbor, MI,
USA), respectively, according to the manufacturer’s instructions.
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Data were expressed as mean ± standard error of the mean (SEM) and were normalized to
the PBS-treated WT control group unless otherwise indicated. Rank-transformed mean
values were compared using a one-way ANOVA followed by Fisher’s LSD post hoc test.
Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC). P<0.05 was
considered statistically significant.
RESULTS
Experiment 1: Relative effect of endothelial CYP2J2 overexpression and high-dose
indomethacin
In pilot studies, high-dose (10 mg/kg) indomethacin significantly inhibited the LPS-
mediated increase in plasma PGEM and 11-dehydro-TxB2 concentrations by 99±0.2% and
77±2%, respectively (p<0.05 versus vehicle, n=6–8 per group). The induction of lung MPO
activity following LPS administration was significantly attenuated in both Tie2-CYP2J2-Tr
and indomethacin (10 mg/kg)-treated WT mice compared to vehicle-treated WT mice
(Figure 1, p<0.05 for each comparison). Furthermore, high-dose indomethacin attenuated
the induction of MPO activity to a significantly greater degree than observed in Tie2-
CYP2J2-Tr mice (67±9% versus 37±11%, respectively, p<0.05).
Experiment 2: Relative effect of incremental indomethacin doses
A dose-response experiment was conducted in order to identify an indomethacin dose that
attenuated LPS-induced vascular inflammation to a similar degree as genetic potentiation of
the CYP epoxygenase pathway. LPS-mediated induction of plasma PGEM (Figure 2A) and
lung MPO activity (Figure 2B) was attenuated by indomethacin in a dose-dependent
manner. Induction of liver MPO activity was also significantly attenuated by indomethacin
at each dose compared to vehicle (Figure 2C); however, a dose-dependent attenuation was
not observed. Since indomethacin 2.5 mg/kg produced a 38±5% attenuation of LPS-induced
lung MPO activity, similar to the 37±11% attenuation observed in Tie2-CYP2J2-Tr mice
from Experiment 1 and the attenuation observed in both Tie2-CYP2J2-Tr and Ephx2−/−
mice from prior studies [9], this “moderate” dose of indomethacin was utilized in
subsequent experiments to evaluate the potential additive effect of simultaneously
modulating both pathways.
Experiment 3: Relative and additive effect of endothelial CYP2J2 overexpression, global
sEH disruption, and moderate-dose indomethacin
LPS-induction of lung MPO activity was significantly attenuated in indomethacin (2.5 mg/
kg)-treated WT (47±3%), Tie2-CYP2J2-Tr (28±10%) and Ephx2−/− (31±8%) mice,
compared to vehicle-treated WT controls (Figure 3A, p<0.05 for each comparison). MPO
activity was decreased in indomethacin-treated Tie2-CYP2J2-Tr (46±5%) and Ephx2−/−
(48±4%) mice to a level similar to that observed in indomethacin-treated WT mice;
however, a significant additive anti-inflammatory effect was not observed (Figure 3A,
p=0.848 and p=0.851, respectively, versus indomethacin-treated WT mice). Similar results
across genotype and treatment groups were observed following LPS-induction of liver MPO
activity (Figure 3B), although the observed attenuation in vehicle and indomethacin-treated
Tie2-CYP2J2-Tr mice was not statistically significant (p=0.397 and p=0.054, respectively,
versus vehicle-treated WT mice).
Indomethacin markedly inhibited the LPS-mediated induction of plasma PGEM, TxB2, and
6-keto-PGF1α levels in WT, Tie2-CYP2J2-Tr, and Ephx2−/− mice (Figure 4A–C, p<0.05
versus vehicle in each genotype group). In contrast, no differences were observed across
genotype within the vehicle or indomethacin-treated groups (Figure 4A–C). Similar results
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were observed with plasma PGD2 and PGF2α levels, and no treatment or genotype
differences in hepatic or pulmonary Ptgs2 mRNA levels were observed (data not shown).
The total sum of EET+DHET levels was approximately 1.3-fold higher in Tie2-CYP2J2-Tr
mice compared to WT (p=0.064) and Ephx2−/− (p=0.047) mice (Figure 4D), consistent with
prior studies [9,18]. The 14:15-EET:DHET ratio was drastically increased in Ephx2−/− mice
compared to WT and Tie2-CYP2J2-Tr mice, irrespective of treatment (Figure 4E, p<0.05
for all comparisons). Indomethacin did not significantly alter the total sum of EET+DHET
levels in Tie2-CYP2J2-Tr mice (p=0.092 versus vehicle) or the 14:15-EET:DHET ratio in
Ephx2−/− mice (p=0.596 versus vehicle). Furthermore, no treatment or genotype differences
in 5-LOX-derived 5-hydroxyeicosatetraenoic acid (5-HETE) or CYP ω-hydroxylase-derived
20-HETE levels were observed (data not shown).
DISCUSSION
Functional characterization of the key eicosanoid metabolism pathways that regulate
vascular inflammatory responses in vivo offers enormous potential to facilitate the
development of new anti-inflammatory therapeutic strategies. Consequently, we investigated
the relative and additive effects of endothelial CYP2J2 overexpression, global sEH
disruption, and pharmacologic COX inhibition on LPS-induced acute vascular inflammation
in mice. Our studies demonstrate that: 1) high-dose indomethacin attenuates acute vascular
inflammation to a significantly greater extent than genetic potentiation of the CYP
epoxygenase pathway; 2) moderate-dose indomethacin attenuates acute vascular
inflammation to a similar degree as either endothelial CYP2J2 overexpression or global sEH
disruption; and, 3) dual modulation of the COX and CYP epoxygenase pathways does not
additively attenuate the acute vascular inflammatory response to LPS. Collectively, these
findings demonstrate that both COX and CYP epoxygenase-mediated eicosanoid
metabolism are important regulators of the acute vascular inflammatory response in vivo,
and suggest that the anti-inflammatory effects of modulating each pathway may be
mediated, at least in part, by overlapping mechanisms.
Consistent with our prior studies and hypothesis, the acute vascular inflammatory response
to LPS was significantly and similarly attenuated in Tie2-CYP2J2-Tr and Ephx2−/− mice
[9], further demonstrating that increased endothelial EET biosynthesis and decreased sEH-
mediated EET hydrolysis elicit potent anti-inflammatory effects in the vasculature in vivo.
Similarly, inhibition of COX-mediated prostaglandin biosynthesis with the nonselective
COX inhibitor indomethacin significantly attenuated vascular inflammation, consistent with
prior studies in various models of inflammation [5]. More specifically, administration of a
moderate (2.5 mg/kg/day) dose of indomethacin elicited an approximate 80% reduction in
LPS-induced plasma PGEM levels and a reduction in pulmonary and hepatic MPO activity
equivalent to that observed in Tie2-CYP2J2-Tr and Ephx2−/− mice. Administration of high
(10 mg/kg/day) dose indomethacin, however, produced a complete abrogation of LPS-
induced PGE2 biosynthesis and a significantly greater anti-inflammatory effect than genetic
potentiation of the CYP epoxygenase pathway. These results suggest that maximizing
inhibition of COX-mediated prostaglandin biosynthesis yields a greater anti-inflammatory
effect than maximizing inhibition of EET hydrolysis via genetic disruption of Ephx2.
Importantly, administration of high doses of nonselective COX inhibitors such as
indomethacin produces substantial, and often intolerable, dose-dependent adverse effects.
Consequently, identifying therapeutic strategies that enhance the anti-inflammatory effects
of lower doses could expand the therapeutic window of COX inhibitors.
Arachidonic acid serves as a common substrate for the parallel biosynthesis of biologically
active COX-, LOX- and CYP-derived eicosanoids. Two recent reports have demonstrated
that COX and sEH inhibition can shunt arachidonic acid metabolism down parallel
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metabolic paths [10,11]. Thus, shunting metabolism away from pro-inflammatory COX-
derived prostaglandins and toward anti-inflammatory CYP-derived EETs would be
hypothesized to yield a greater anti-inflammatory effect than modulation of either pathway
alone. Indeed, an additive attenuation of LPS-induced pain [13] and hypotension [12]
following dual inhibition of COX and sEH has been reported, suggesting that functional
interactions exist between COX- and CYP epoxygenase-mediated arachidonic acid
metabolism (i.e., where modulation of one pathway enhances the effects of the other). The
effects of COX inhibition in tandem with potentiation of CYP-derived EETs on vascular
inflammation, however, had not been evaluated to date. The current investigation
demonstrates that despite anti-inflammatory effects following modulation of each pathway
alone, simultaneous inhibition of COX-derived prostaglandin biosynthesis and potentiation
of CYP epoxygenase-derived EET levels does not additively attenuate the acute vascular
inflammatory response to LPS in vivo. Although indomethacin has been previously reported
to inhibit CYP epoxygenase activity in vitro [22], the observed IC50 in these experiments
(70 μM) was more than 20-fold above the peak plasma concentrations following high dose
(10 mg/kg) treatment in rodents [23]. In the current investigation, in vivo EET levels were
not significantly suppressed by indomethacin in WT, Tie2-CYP2J2-Tr or Ephx2−/− mice.
Moreover, an increase in metabolism down the parallel 5-LOX and CYP ω-hydroxylase
pathways was not observed. Thus, the observed lack of an additive anti-inflammatory effect
was not secondary to indomethacin-mediated inhibition of EET biosynthesis or shunting
arachidonic acid metabolism down a parallel pro-inflammatory pathway. Although the
specific mechanism remains unclear, these data collectively suggest that the vascular anti-
inflammatory effects of COX inhibition and increasing EET levels may be mediated by an
overlapping mechanism.
Prior evidence has demonstrated the presence of metabolic and functional crosstalk between
the CYP epoxygenase and COX pathways, independent of arachidonic acid substrate
shunting. Most notably, EETs have been reported to inhibit COX enzymatic activity in ram
seminal vesicles, rat monocytes and murine vascular smooth muscle cells in vitro [24–26],
suppress LPS-induction of hepatic and spinal COX-2 expression in vivo [13,27,28], and
consequently attenuate the induction of pro-inflammatory prostaglandin biosynthesis
[13,25–28]. These observations suggest that inhibition of prostaglandin biosynthesis may
contribute to the anti-inflammatory effects of EETs. In the presence of genetic potentiation
of EET levels, however, we did not observe any significant differences in prostaglandin
levels. Similar results were recently reported following induction of tumor growth in these
genetically-modified mice [18]. Collectively, this suggests that EET-mediated attenuation of
prostaglandin biosynthesis does not contribute to the acute vascular anti-inflammatory
phenotype observed in Tie2-CYP2J2-Tr and Ephx2−/− mice.
It has also been reported that EETs induce COX-2 expression and prostacyclin production in
cultured endothelial cells in the absence of an inflammatory stimulus [29], suggesting that
EET-mediated modulation of prostaglandin biosynthesis may be dependent on the specific
model or cell type under investigation. Endotoxin-induced hypotension and nociception are
phenotypes primarily driven by inducible nitric oxide synthase-mediated vasodilation [30]
and cAMP-mediated signaling [27,31], respectively, as compared to induction of CAM and
chemokine-mediated endothelial activation and leukocyte infiltration into tissue [14].
Furthermore, the hypotension and pain phenotypes that were additively attenuated by dual
modulation of the COX and CYP epoxygenase pathways were assessed 6 hours following
LPS administration [12,13]. In contrast, we measured MPO activity, an established
biomarker of neutrophil infiltration, 3 hours following LPS administration [9]. Since
induction of inflammatory CAM, chemokine and cytokine expression peaks 2–4 hours
following administration of LPS [32,33], functional interactions between EET and
prostaglandin biosynthesis may be unmasked at later time points during resolution of the
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acute inflammatory response. These findings collectively highlight the complexity of
initiation and resolution of the acute inflammatory response, and the potential contribution
of temporal and phenotypic differences to the role of eicosanoid metabolism in the
regulation of inflammation.
More recently, EETs have been reported to selectively antagonize recombinant Tx (TP)
receptors, with little or no binding affinity for non-TP prostanoid or leukotriene receptors,
and specifically inhibit TP receptor agonist-mediated constriction of isolated rodent
resistance arteries, conduit arteries and bronchi [34]. In accordance, EETs also blocked TP
receptor agonist-mediated constriction of isolated human bronchi, while administration of a
CYP epoxygenase inhibitor increased TP-dependent bronchoconstriction [35]. Additionally,
EETs inhibit arachidonic acid-stimulated platelet aggregation in isolated human platelets
without changing Tx levels [24], further corroborating the potential presence of redundancy
in the biological effects of increasing CYP-derived EET and decreasing COX-derived TxA2
levels. Importantly, activation of TP-receptor signaling also drives acute and chronic
vascular inflammatory responses, including cytokine-mediated activation of leukocyte
adhesion [7] and diabetes-induced atherosclerosis [36]. Considering the lack of an additive
anti-inflammatory effect following dual modulation of the COX and CYP epoxygenase
pathways in the current investigation, it is conceivable that attenuation of TP receptor
signaling contributes, at least in part, to the vascular anti-inflammatory effects of both COX
inhibition (via inhibiting TxA2 biosynthesis) and increasing CYP-derived EETs (via
competitive inhibition of TP receptors). These observations collectively highlight the
importance for future studies to elucidate functional interactions between EETs and TP
receptor signaling in the regulation of vascular inflammation. Furthermore, thoroughly
understanding the relative roles of, functional interactions between and mechanisms
underlying the parallel CYP epoxygenase, CYP ω-hydroxylase, COX (including the specific
prostaglandin synthases and receptors), and LOX pathways of arachidonic acid metabolism
in the regulation of acute and chronic vascular inflammatory responses will be essential in
order to maximize the anti-inflammatory therapeutic potential of targeting eicosanoid
metabolism.
CONCLUSIONS
Although potentiation of the CYP epoxygenase pathway, through increased EET
biosynthesis or decreased EET hydrolysis, and non-selective inhibition of COX-mediated
prostaglandin biosynthesis each attenuated the acute vascular inflammatory response to
endotoxin in vivo, dual modulation of both pathways did not result in an additive anti-
inflammatory effect. These findings further demonstrate that both the COX and CYP
epoxygenase pathways are important regulators of vascular inflammation, and suggest that
the anti-inflammatory effect of modulating each pathway may be mediated, at least in part,
by overlapping mechanisms. Future studies delineating the complex functional interactions
between these parallel metabolic pathways in the regulation of inflammation are necessary.
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• CYP2J2 overexpression and sEH disruption each attenuate acute vascular
inflammation.
• Moderate dose indomethacin attenuates vascular inflammation to a similar
degree.
• Modulation of both pathways did not produce an additive anti-inflammatory
effect.
• These anti-inflammatory effects may be mediated by overlapping mechanisms.
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Figure 1. Relative effect of endothelial CYP2J2 overexpression and high-dose indomethacin on
acute vascular inflammation
LPS-induced lung MPO activity in indomethacin- (10 mg/kg) and vehicle-treated wild-type
(WT) mice and Tie2-CYP2J2-Tr mice. Data are expressed relative to saline (PBS)-treated
WT controls. N=6–8 per group. *P<0.05 versus LPS WT-vehicle. #P<0.05, indomethacin
versus CYP2J2-Tr.
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Figure 2. Dose-dependent inhibition of acute vascular inflammation by indomethacin
LPS-induced (A) plasma PGEM levels, (B) lung MPO activity, (C) and liver MPO activity
following administration of vehicle (Veh) or incremental doses of indomethacin (1, 2.5, 5 or
10 mg/kg) to wild-type C57BL/6 mice. Data are expressed relative to saline (PBS) and Veh-
treated controls. The mean PGEM levels in the PBS control group and LPS-treated vehicle
group were 6.6 and 658 pg/mL, respectively. N=4–9 per group. *P<0.05 versus LPS-
vehicle.
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Figure 3. Relative effect of endothelial CYP2J2 overexpression, global sEH disruption, and
moderate-dose indomethacin on acute vascular inflammation
LPS-induced (A) lung MPO activity and (B) liver MPO activity following administration of
vehicle or indomethacin (2.5 mg/kg) to wild-type (WT), Tie2-CYP2J2-Tr, and Ephx2−/−
mice. Data are expressed relative to saline (PBS)-treated WT controls. PBS: N=6 per group,
LPS: N=9–18 per group. *P<0.05 versus LPS WT-vehicle. NS=not significant.
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Figure 4. Relative effect of endothelial CYP2J2 overexpression, global sEH disruption, and
moderate-dose indomethacin on eicosanoid metabolite levels
LPS-induced plasma (A) PGEM, (B) TxB2, and (C) 6-keto-PGF1α levels, (D) the total sum
of EET+DHETs, and (E) the 14,15-EET:DHET ratio following administration of vehicle or
indomethacin (2.5 mg/kg) to wild-type (WT), Tie2-CYP2J2-Tr, and Ephx2−/− mice. The
mean eicosanoid levels for the PBS control group are as follows: (A) PGEM, below the limit
of detection (the mean level in the LPS-treated WT group is 379 pg/mL); (B) TxB2, 214 pg/
mL; (C) 6-keto-PGF1α, 49.5 pg/mL; (D) sum of EET+DHETs, 13.7 ng/mL; (E) 14,15-
EET:DHET, 0.035 (ratio). PBS: N=5 per group, LPS: N=9–16 per group. *P<0.05 versus
LPS WT-vehicle. #P<0.05, indomethacin versus vehicle within the Tie2-CYP2J2-Tr and
Ephx2−/− genotype groups. ND=below the limit of detection. NS=not significant.
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